Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > simple disclosure
View:
Post by M101 on Apr 18, 2022 12:24pm

simple disclosure

"Argus Research Co. has received a flat fee from the company discussed in this report as part of a Sponsored Research agreement between Argus and the company."

I like that our promotional expenses are getting better transparency.  That BS with Mackie did nothing for corporate credibility, and Goldstein knew it but he did it anyway. 
Comment by azzymaa on Apr 18, 2022 12:35pm
Here is m101 talking about absolutely nothing and making up his own false conclusions. Reported.
Comment by FarmerBetty on Apr 18, 2022 12:54pm
M101, has it right !! They keep bringing out timbits of information bought by Promisneurosciences through different outlets. The share price is positioned by Eugene and Elliot, Fidelity etc. Watch for the next Boston group grab??
Comment by garygp on Apr 18, 2022 3:56pm
My turn to wade in here.  I want it clearly understood that the ONLY REASON I am still here is Dr. Neil Cashman, his science, and integrity.  All the rest of the dead beat BOD with the possible exception of Warma and Kaplan can can go straight to he!! and stay there.  Sadly, I bought the story from Gene and Elliot early on and wasted a pile of time, money and energy on PMN.  ...more  
Comment by azzymaa on Apr 18, 2022 5:36pm
Gary, finally someone with common sense instead of m101 blabbering left right and center. 
Comment by FarmerBetty on Apr 18, 2022 8:32pm
Elliott, you have to stop the nonsense for someone who cashed and has posted more than anyone else over the last two weeks.  M101, has called it correctly over the past months, others have been on Biogen and other side kicks, a side distraction. After all these years of Cashman's science with more and more mouse validations it's time to call it ?
Comment by azzymaa on Apr 19, 2022 9:08am
M101 has not called out anything, show me any proof in their post history. Pathetic. Welcome to a new CMO at Promis, previously VP at Phizer!
Comment by FarmerBetty on Apr 19, 2022 9:17am
Yes, what a joke another Phizer name with no worthy news!! Elliott and Eugene, the con artist!!! Isn't news, will catch up with them!!
Comment by M101 on Apr 19, 2022 12:55am
I agree with Gary but I have this nagging doubt that any of us would be on this board if not for Gene and Elliot's failings.  I mean if Martin Tolar had stumbled onto Amorfix in 2015 instead of our two clowns then it wouild have gone private with my shares forced out of my hands at a pittance.  Promis now is an anachronism to the market, it shouldn't exist publicly traded and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities